Osagie Obasogie and Marcy Darnovsky’s Beyond Bioethics: Toward a New Biopolitics
By Travis Chi Wing Lau,
Somatosphere [review of the book edited by CGS' Osagie K Obasogie and Marcy Darnovsky]
| 09. 13. 2018
“The science will let loose its cascading interactions with utter impassivity; yet how we inhabit that knowledge will be a contest of the imagination, a sedimentation of political futures, a constructed infinity of worlds.” —Patricia J. Williams
What are the consequences of a bioethics that fails to keep up? With the rapid development of new biotechnologies like CRISPR, Beyond Bioethics makes a timely call for a novel take on bioethics capable of addressing the significant sociopolitical implications of these technologies. The contributors to this volume make clear that triumphalist cultural narratives of scientific innovation and progress have obfuscated and even impeded necessary ethical conversations about the development and application of biotechnologies too often touted as the future of biomedicine. Each of the 54 essays in this collection demonstrates how current bioethical frameworks and vocabularies fail to effectively grapple with the complex, intersectional problems that come with assisted reproduction or human genetic modification. Bridging together thinkers across the humanities and sciences divide, Beyond Bioethics models a progressive, interdisciplinary approach to bioethics that extends beyond a focus on the individual toward...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...